Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT06402968 Not yet recruiting - Stroke Clinical Trials

Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

CLUTCH
Start date: June 1, 2024
Phase:
Study type: Observational

The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.

NCT ID: NCT06401759 Recruiting - Hypertension Clinical Trials

Use of Podcasts in the Education of Hypertension Patients

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

Hypertension is an important public health problem all over the world due to its high prevalence and its association with increased risk of cardiovascular disease. At the same time, it is a condition in which acquired factors, genetic and metabolic disorders, characterized by increased intra-arterial blood pressure, occur together . According to the World Health Organization, hypertension is defined as systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or above According to the Arterial Hypertension Management 2018 Implementation Guide of the European Society of Cardiology and the European Society of Hypertension, it is estimated that there are more than 1 billion hypertension patients in the world and this number will reach 1.5 billion by 2025. In our country, there are approximately 20 million individuals with hypertension. It is thought to be Hypertension treatment is a lifelong process that includes lifestyle changes and patient education along with medical treatment.Turkish Endocrinology and Metabolism. The aim of hypertension treatment is to ensure that blood pressure decreases to the targeted level, to minimize target organ damage and complications caused by hypertension, to eliminate symptoms and reduce drug side effects, to ensure patient compliance with treatment and to provide self-management skills by enabling the patient to take an active role in his own treatment. The concept of self-management; It includes providing individuals with knowledge and skills regarding disease management, providing support to maintain the individual's self-care, supporting the decision-making process, and helping to recognize and cope with problems. The main goal in hypertension treatment is to control the patient's blood pressure. Achieving and maintaining self-management is also one of the most effective factors in controlling blood pressure. Inadequately treated and low self-management In hypertension patients, blood pressure control is inadequate and health risks increase. Therefore, all strategies implemented to increase self-management in hypertension patients also have positive effects on the individual's blood pressure control and disease prognosis.

NCT ID: NCT06401278 Recruiting - Hypertension Clinical Trials

Trans Cutaneous Electrical Acupoint Stimulation Versus TENS On Blood Pressure In Primary Hypertension Patients

Start date: May 5, 2024
Phase: N/A
Study type: Interventional

To compare between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension BACKGROUND: The current American College of Cardiology and the American Heart Association (ACC/AHA) 2017 guidelines define hypertension as systolic BP (SBP) of ≥130 mmHg or diastolic BP (DBP) of ≥80 mmHg. In adults, an increase of 20 mmHg in SBP or 10 mmHg in DBP is associated with more than a two-fold increase in mortality owing to stroke and other cardiovascular diseases. Hypertension accounts for 13% of premature deaths worldwide and is the third leading cause of disability-adjusted life years (Shah et al., 2022). Transcutaneous electrical nerve stimulation of the Neiguan (P6) point with acupressure is possibly affecting the blood pressure by protecting the myocardial tissues and influencing the nervous system through regulating the autonomic nervous system function and reduction in sympathetic activity. (Hassanein et al., 2021). HYPOTHESES There will be no a significant difference between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension RESEARCH QUESTION: Is there a significant difference between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension? Evaluating equipment, pre-post intervension outcomes: 1. BP by Digital Sphygmomanometer 2. quality of life by The SF-12 health status questionnaire 3. nitric oxide level in blood by nitric Oxide analysis. 4. sleep quality. by Pittsburgh Sleep Quality Index (PSQI) 5. exercise capacity and endurance by Thirty-Second Sit-To-Stand Test (30 STST)

NCT ID: NCT06397456 Not yet recruiting - Hypertension Clinical Trials

Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy

iPREP RRT
Start date: May 2024
Phase: N/A
Study type: Interventional

Intensive Patient Referral and Education Program prior to Renal Replacement Therapy (iPREP RRT) is a 12-week intervention that identifies hospitalized African Americans with advanced chronic kidney disease(CKD) and provides them with hospital- and community-based education, navigation and self-management support. Participants will be randomized to the iPREP RRT intervention versus enhanced usual care.

NCT ID: NCT06395194 Completed - Clinical trials for Essential Hypertension

Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension

VALUE
Start date: September 27, 1997
Phase: Phase 3
Study type: Interventional

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial tested the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. The present study investigates effects of valsartan and amlodipine on pre-specified secondary kidney outcomes.

NCT ID: NCT06394973 Not yet recruiting - Glaucoma Clinical Trials

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Start date: July 2024
Phase: Phase 2
Study type: Interventional

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution

NCT ID: NCT06394934 Recruiting - Hypertension Clinical Trials

Home Blood Pressure Variability and Its Link to Arteriosclerosis and Metabolic Dysfunction in Hypertensive Patients

Start date: January 9, 2024
Phase:
Study type: Observational [Patient Registry]

This observational study investigates the correlation between home blood pressure variability (BPV) and arteriosclerosis, alongside metabolic indicators, in hypertensive patients over a three-year period. The research specifically focuses on the predictive value of home BPV for major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and heart failure hospitalizations. Utilizing a mobile application called Healthscan for daily BP monitoring, the study aims to enhance the understanding of how BPV impacts cardiovascular and metabolic health in a real-world setting.

NCT ID: NCT06393621 Completed - Prehypertension Clinical Trials

Investigate the Effectiveness of KEFPEP® on Regulating High Blood Pressure

Start date: July 26, 2018
Phase: N/A
Study type: Interventional

To assess the ability of KEFPEP® to reduce blood pressure

NCT ID: NCT06391073 Not yet recruiting - Hypertension Clinical Trials

Reach Out 2: Emergency Department-Initiated Hypertension Mobile Health Intervention Connecting Multiple Health Systems

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Emergency department visits provide an opportunity to identify people with undiagnosed, untreated, or uncontrolled high blood pressure. In Reach Out, we will test whether a mobile health intervention yields a greater reduction in blood pressure than usual care among individuals identified with high blood pressure during a safety-net emergency department visit. Subsequently, we will estimate the reduction in heart attack, stroke, and dementia if Reach Out were implemented across all U.S. safety-net emergency departments.

NCT ID: NCT06388421 Not yet recruiting - Clinical trials for Pulmonary Hypertension

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Start date: August 1, 2024
Phase:
Study type: Observational

This is a prospective, non-interventional, multicenter, registry of patients with pulmonary associated with interstitial lung disease (PH-ILD).